glp-1 washington - Patients lose “spectacular” amounts of weight on Eli Lilly's medicine. But doctors say with greater potency comes greater risk. https://wapo.st/3RR0GLG GLP-1 Drugs Archives | Washington

doi:10.1007/s00018-010-0398-3 116

It activates both GIP and GLP-1 receptors, which together regulate appetite, metabolism, and blood sugar more effectively than medications that focus on a single hormone

The absolute risk increase for diabetic retinopathy complications was greater among patients with a history of diabetic retinopathy at baseline (semaglutide 8.2%, placebo 5.2%) than among patients without a known history of diabetic retinopathy (semaglutide 0.7%, placebo 0.4%)

For other concerns, it is important not to stop the medication abruptly without medical advice, as this could affect diabetes control or weight management